GE Healthcare, a unit of General Electric Company (NYSE: GE), announced that it has completed the acquisition of the assets of Orbotech Medical Solutions Ltd. (OMS), a subsidiary of Orbotech Ltd. (Orbotech), and a manufacturer of cadmium zinc telluride (CZT) detectors used in GE Healthcare’s innovative Alcyone nuclear medicine technology. “We’re pleased to announce that through the acquisition of OMS, we have passed an important milestone in the growth of GE Healthcare’s Nuclear Medicine business,” said Nathan Hermony, general manager Nuclear Medicine for GE Healthcare. Representing a major development in nuclear medicine technology, GE Healthcare’s Alcyone technology combines CZT detectors, focused pin-hole collimation, 3D reconstruction, and stationary data acquisition to reduce acquisition time and dose, improve workflow while maintaining image quality. Alcyone technology enables views of cardiac anatomy and functionality with greater clarity and speed, resulting in scan times as short as three minutes or up to a four-fold reduction in dose. GE Healthcare recently announced FDA clearance of the use of CZT technology in assessment and early detection of breast cancer in women who are at high risk for the disease. The Discovery NM750b Molecular Breast Imaging (MBI) system utilises a small Field of View CZT gamma camera dedicated to breast imaging. The innovation of the MBI technology is the use of CZT, to replace the standard Sodium Iodine detectors routinely used for gamma cameras, in a dedicated breast and small organ device. This technology is intended to improve early detection of breast cancer, especially in women who are less likely to benefit from conventional mammography, as in cases of dense breast where imaging results may be inconclusive.
- Genetic health risks may arise due to assisted reproductive technology
- Internet exposure may pose hazard to health